16h
Hosted on MSNGLP-1 Drugs and Colonoscopy; GI Symptoms Post-COVID; Identifying High-Risk Barrett'sA systematic review and meta-analysis of five studies suggested that patients on GLP-1 receptor agonists were more likely to ...
Eli Lilly continues to see strong growth coming from its GLP-1 drugs. The company's current 2025 guidance looks conservative.
It’s possible that GLP-1s may be useful for a range of substance use disorders, including opioid use disorder and nicotine ...
The following contains links to social media websites including Bluesky, X, TikTok, Instagram, Facebook, and LinkedIn. "Make ...
People with type 2 diabetes who take GLP-1 and SGLT-2 medications have a lower risk of having COPD symptom flare-ups than ...
These and other GLP1-RA diabetes/weight-loss meds can also boost outcomes for folks battling chronic kidney disease, new ...
As demand remains high for GLP-1 drugs, primary care physicians are concerned about the risks of patients using third-party ...
A majority with overweight/obesity discontinue within a year, but the rate is higher among those without type 2 diabetes.
Independence Blue Cross began limiting coverage of GLP-1 drugs on Jan. 1 to some medical conditions, but not obesity or weight loss.
A small semaglutide trial suggests the medicine's suppression of appetite may extend to alcohol, but larger tests are needed ...
Hims & Hers hit the bullseye with its Super Bowl ad, sparking a surge in clicks to its site.The ad also hit a nerve with the ...
A small percentage have had vision problems, but a direct causal link with the drugs has not been established.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results